BIND-014 is a targeted polymeric nanoparticle, and is an investigational therapeutic drug in phase 2 clinical trials for various cancers, e.g. metastatic prostate cancerBIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc. Wikipedia